Companies Rani Therapeutics Holdings, Inc.
Rani Therapeutics (RANI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Rani Therapeutics Holdings, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,042,245FY2024
- $1,052,101FY2025
CEO total pay was $1,052,101 in fiscal 2025, down from $3,042,245 in fiscal 2024.
FY2025: salary $198,325 · bonus $0 · stock awards $0 · option awards $502,176
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Talat Imran | $198,325 | $0 | $0 | $502,176 | $351,600 | $0 | $0 | $1,052,101 |
| Chief Executive Officer | ||||||||
| Svai Sanford | 392,711 | 139,000 | 0 | 154,993 | 259,700 | 0 | 0 | 946,404 |
| Chief Financial Officer | ||||||||
| Kate McKinley | 370,472 | 130,000 | 0 | 201,565 | 241,900 | 0 | 0 | 943,937 |
| Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Talat Imran | $1,052,101 | $3,042,245 | — | ↓ −1,990,144 |
| Svai Sanford | 946,404 | 1,291,456 | — | ↓ −345,052 |
| Kate McKinley | 943,937 | 1,265,456 | — | ↓ −321,519 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is not explicitly detailed in a dedicated section, but the CD&A indicates that compensation is designed to align executive interests with corporate goals, including financing, partnering, and clinical milestones, while also reflecting cash preservation efforts through voluntary salary reductions and retention programs.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Talat Imran | OPTION | 2025-05-23 | — | — | 1,053,000 | — | $502,176 |
| Kate McKinley | OPTION | 2025-05-23 | — | — | 325,000 | — | 154,993 |
| Kate McKinley | OPTION | 2025-08-01 | — | — | 120,000 | — | 46,572 |
| Svai Sanford | OPTION | 2025-05-23 | — | — | 325,000 | — | 154,993 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Talat Imran | $0 | $0 | $502,176 | 0.0% |
| Kate McKinley | 0 | 0 | 201,565 | 0.0% |
| Svai Sanford | 0 | 0 | 154,993 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Svai Sanford | Option | 6,250 | 2.84 | — |
| Svai Sanford | RSU | 8,225 | — | 11,104 |
| Imran | Option | 16,463 | 2.84 | — |
| Imran | RSU | 21,650 | — | 29,228 |
| Svai Sanford | RSU | 43,438 | — | 58,641 |
| Svai Sanford | Option | 64,313 | 2.84 | — |
| Kate McKinley | Option | 88,542 | 2.84 | — |
| Imran | RSU | 110,469 | — | 149,133 |
| Imran | Option | 179,875 | 2.84 | — |
| Svai Sanford | Option | 181,969 | 3.6 | — |
| Kate McKinley | Option | 181,969 | 3.6 | — |
| Svai Sanford | Option | 277,605 | 0.62 | — |
| Kate McKinley | Option | 277,605 | 0.62 | — |
| Imran | Option | 610,313 | 3.6 | — |
| Imran | Option | 899,438 | 0.62 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Vasudev BaileyIndependent · Compensation (Chair) · Newly elected | $15,000 | — | $168,820 | — | — | $183,820 |
| Abraham BassanIndependent · Nominating and Corporate Governance (Chair) · Newly elected | 13,750 | — | 168,820 | — | — | 182,570 |
| Maulik NanavatyIndependent · Compensation (Chair) · Departed during FY | 8,438 | — | 75,347 | — | — | 83,784 |
| Andrew FarquharsonNot independent · Departed during FY | 5,625 | — | 75,347 | — | — | 80,972 |
| Mir ImranNot independent · Board Chair | 30,000 | — | 23,270 | — | — | 53,270 |
| Lisa RomettyIndependent · Audit (Chair) · Nominating and Corporate Governance · Compensation | 23,375 | — | 23,270 | — | — | 46,645 |
| Jean-Luc ButelIndependent · Audit · Nominating and Corporate Governance · Compensation | 21,938 | — | 23,270 | — | — | 45,208 |
| Dennis AusielloIndependent · Audit · Compensation | 20,500 | — | 23,270 | — | — | 43,770 |
| Laureen DeBuonoIndependent · Compensation · Departed during FY | 13,125 | — | 0 | — | — | 13,125 |
| Talat ImranEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $151,751 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $151,751 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Rani Therapeutics as a peer
Companies that benchmark against RANI
No companies currently name RANI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rani Therapeutics Holdings, Inc. | 2025 | Talat Imran | $198,325 | $0 | $502,176 | $351,600 | $1,052,101 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (21 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Talat Imran. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 23. As printed: 1,052,101. View filing ↗
- Section 01, Svai Sanford. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 23. As printed: 946,404. View filing ↗
- Section 01, Kate McKinley. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 23. As printed: 943,937. View filing ↗
- Section 03, Talat Imran OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kate McKinley OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kate McKinley OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Svai Sanford OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Vasudev Bailey. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 183,820. View filing ↗
- Section 08, Abraham Bassan. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 182,570. View filing ↗
- Section 08, Maulik Nanavaty. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 83,784. View filing ↗
- Section 08, Andrew Farquharson. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 80,972. View filing ↗
- Section 08, Mir Imran. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 53,270. View filing ↗
- Section 08, Lisa Rometty. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 46,645. View filing ↗
- Section 08, Jean-Luc Butel. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 45,208. View filing ↗
- Section 08, Dennis Ausiello. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 43,770. View filing ↗
- Section 08, Laureen DeBuono. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 13,125. View filing ↗
- Section 08, Talat Imran. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 151,751 + equity 0 + all other 0 = 151,751, summed across the director compensation table rows.
- Rani Therapeutics Holdings, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Rani Therapeutics Holdings, Inc.'s own proxy. As printed: 1,052,101. View filing ↗